Limited Coverage Drugs - Rivaroxaban for the treatment of deep vein thrombosis (DVT) or pulmonary embolism (PE)
|rivaroxaban for deep vein thrombosis (DVT) or pulmonary embolism (PE) treatment|
|15 mg and 20 mg|
|Special Authority Criteria||Approval Period|
|For the treatment of patients with DVT or PE.||Up to 6 months total|
- The recommended dose of rivaroxaban for patients initiating DVT or PE treatment is 15 mg twice daily for three weeks, followed by 20 mg once daily.
- PharmaCare coverage of rivaroxaban for the treatment of DVT or PE is an alternative to heparin/warfarin for up to six months. When used for longer than six months, rivaroxaban is more costly than heparin/warfarin. As such, patients with an intended duration of therapy longer than six months should be considered for initiation on heparin/warfarin.
- Since renal impairment can increase bleeding risk, it is important to monitor renal function regularly. Other factors that increase bleeding risks should also be assessed and monitored (see product monograph).